{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:31:42Z","timestamp":1784309502512,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009844","name":"PA Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ECF APP1111136"],"award-info":[{"award-number":["ECF APP1111136"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001061","name":"Rebecca L. Cooper Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jpsychires.2020.02.015","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T08:52:27Z","timestamp":1582015947000},"page":"9-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)"],"prefix":"10.1016","volume":"124","author":[{"given":"Dan","family":"Siskind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2020.02.015_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.jpsychires.2020.02.015_bib2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"The Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta\u2010analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","article-title":"Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-\u03b1 in mice","volume":"54","author":"Maida","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jpsychires.2020.02.015_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjpo.bp.115.001073","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial","volume":"1","author":"Mayfield","year":"2015","journal-title":"BJPsych open"},{"key":"10.1016\/j.jpsychires.2020.02.015_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0269881115625496","article-title":"Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes","volume":"30","author":"Mayfield","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-15-0074","article-title":"Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance","volume":"227","author":"Remington","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2020.02.015_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156208","article-title":"Metformin for clozapine associated obesity: a systematic review and meta-analysis","volume":"11","author":"Siskind","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jpsychires.2020.02.015_bib13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine\u2010associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/acps.12982","article-title":"One\u2010year follow\u2010up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine\u2010or olanzapine\u2010treated patients","volume":"139","author":"Svensson","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2020.02.015_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int. J. Obes."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395619311355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395619311355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:13:53Z","timestamp":1758366833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395619311355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":15,"alternative-id":["S0022395619311355"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.02.015","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX)","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}